Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis.
Autor(es): Miyagi F.; Horiuchi H.; Nagata I.; Kitahara S.; Kiyoki M.; Komoriya K.; Yuki N.
Resumo: To clarify how intravenous immunoglobulin (IVIg) acts on Guillain-Barré syndrome, we investigated the effects of intact-type IVIg treatment on experimental allergic neuritis (EAN) induced by immunizing with synthetic peptide from bovine P2 protein. Treatment with intact-type IVIg (400 mg/kg/day) on days 0, 7, 14, 15 and 16 after immunization prevented the paralysis, whereas treatment with F(ab')2 failed to alter the clinical course. Intact-type IVIg treatment given on days 0 and 1 showed almost the same efficacy. These results suggest that intact-type IVIg is superior to F(ab')2 in ameliorating the clinical course of EAN and that the Fc portion might affect the immune system.
Imprenta: Journal of Neuroimmunology, v. 78, n. 1-2, p. 127-131, 1997
Identificador do objeto digital: 10.1016/S0165-5728(97)00090-8
Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Immunology ; Guillain-Barre Syndrome - Public health
Data de publicação: 1997
